CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients

Tumor Biology

Volumn 36, Issue 8, 2015, Pages 5943-5951

  Facchinetti, Francesco ^a   Aldigeri, Raffaella ^b   Aloe, Rosalia ^a   Bortesi, Beatrice ^a   Ardizzoni, Andrea ^c   Tiseo, Marcello ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Carcinoembryonic antigen; Early predictive marker; Epidermal growth factor receptor; Non small cell lung cancer

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; CARCINOEMBRYONIC ANTIGEN BINDING PROTEIN, HUMAN; CELL SURFACE RECEPTOR; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; EGFR GENE; FEMALE; GENE MUTATION; HUMAN; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; NON SMALL CELL LUNG CANCER; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; BIOSYNTHESIS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; ERBB RECEPTORS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; TREATMENT OUTCOME;

EID: 84940436258     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3269-6     Document Type: Article

References (28)

1. Shepherd FA, Rodriguez Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. National cancer institute of Canada clinical trials group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.
2. Mok TS, Wu Y-L, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
3. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.
4. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–44.
5. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled, phase III study. Lancet Oncol. 2010;11:521–9.
6. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol. 1993;11:607–15.
7. Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. 1999;17:501–8.
8. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76:138–43.
9. Stieber P, Zimmermann A, Reinmiedl J, Muller C, Hoffmann H, Dienemann H. CYFRA 21–1 in the early diagnosis of recurrent disease in non-small-cell lung carcinomas (NSCLC). Anticancer Res. 1999;19:665–8.
10. Pujol JL, Molinier O, Ebert W, Daurès JP, Barlesi F, Buccheri G, et al. CYFRA 21–1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer. 2004;90:2097–105.
11. Vollmer RT, Govindan R, Graziano SL, Gamble G, Garst J, Kelley MJ, et al. Serum CYFRA 21–1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res. 2003;9:1728–33.
12. Holdenrieder S, Von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, et al. Nucleosomes and CYFRA 21–1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer. 2008;63:128–35.
13. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in advanced non-small-cell lung cancer. Cancer. 2006;107:2842–9.
14. Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, et al. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer. 2010;67:355–60.
15. Therasse P, Arbuck SG, Esenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.
16. Chiu CH, Shih YN, Tsai CM, Liou JL, Chen YM, Perng RP. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib. Lung Cancer. 2007;57:213–21.
17. Zhang Y, Jin B, Shao M, Dong Y, Lou Y, Huang A, et al. Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. Tumor Biol. 2014;35:4921–8.
18. Barlési F, Tchouhadjian C, Doddoli C, Torre JP, Astoul P, Kleisbauer JP. CYFRA 21–1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy. Br J Cancer. 2005;92:13–4.
19. Okamoto T, Nakamura T, Ikeda J, Maruyama R, Shoji F, Miyake T, et al. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer. 2005;41:1286–90.
20. Shoji F, Yoshino I, Yano T, Kometani T, Ohba T, Kouso H, et al. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer. 2007;110:2793–8.
21. Kappers I, Vollebergh MA, Van Tinteren H, Korse CM, Nieuwenhuis LL, Bonfrer JM, et al. Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment. Ecancermedicalscience. 2010;4:178.
22. Jung M, Kim SH, Lee YJ, Hong S, Kang YA, Kim SK, et al. Prognostic and predictive value of CEA and CYFRA 21–1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med. 2011;2:685–93.
23. Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, et al. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. J Thorac Oncol. 2013;8:892–8.
24. Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, et al. Predictive role of CEA and CYFRA 21–1 in patients with advanced-stage NSCLC treated with erlotinib. Anticancer Res. 2014;34:3205–10.
25. Wirth T, Soeth E, Czubayko F, Juhl H. Inhibition of endogenous carcinoembryonic antigen (CEA) increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth. Clin Exp Metastasis. 2002;19:155–60.
26. Ordonez C, Screaton RA, Ilantzis C, Stanners CP. Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res. 2000;60:3419–24.
27. Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, et al. Early prediction of nonprogression in advanced non–small-cell lung cancer treated with erlotinib by using [18F] Fluorodeoxyglucose and [18F]fluorothymidine positron emission tomography. J Clin Oncol. 2011;29:1701–8.
28. Tiseo M, Ippolito M, Scarlattei M, Spadaro P, Cosentino S, Latteri F, et al. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. Cancer Chemother Pharmacol. 2014;73:299–307.